These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16911854)

  • 1. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients.
    Vergouwe Y; Steyerberg EW; Foster RS; Sleijfer DT; Fosså SD; Gerl A; de Wit R; Roberts JT; Habbema JD
    Eur Urol; 2007 Feb; 51(2):424-32. PubMed ID: 16911854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
    Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
    Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
    Steyerberg EW; Keizer HJ; Fosså SD; Sleijfer DT; Toner GC; Schraffordt Koops H; Mulders PF; Messemer JE; Ney K; Donohue JP
    J Clin Oncol; 1995 May; 13(5):1177-87. PubMed ID: 7537801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
    Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
    Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.
    Steyerberg EW; Gerl A; Fossá SD; Sleijfer DT; de Wit R; Kirkels WJ; Schmeller N; Clemm C; Habbema JD; Keizer HJ
    J Clin Oncol; 1998 Jan; 16(1):269-74. PubMed ID: 9440752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
    Fosså SD; Qvist H; Stenwig AE; Lien HH; Ous S; Giercksky KE
    J Clin Oncol; 1992 Apr; 10(4):569-73. PubMed ID: 1312586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
    Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer.
    Vergouwe Y; Steyerberg EW; Foster RS; Habbema JD; Donohue JP
    J Urol; 2001 Jan; 165(1):84-8; discussion 88. PubMed ID: 11125370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
    Steyerberg EW; Keizer HJ; Messemer JE; Toner GC; Schraffordt Koops H; Fosså SD; Gerl A; Sleijfer DT; Donohue JP; Habbema JD
    Cancer; 1997 Jan; 79(2):345-55. PubMed ID: 9010108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: the danger of postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma.
    Spermon JR; Witjes JA
    J Endourol; 2008 May; 22(5):1013-6. PubMed ID: 18429687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroperitoneal lymph node dissection after chemotherapy.
    Winter C; Raman JD; Sheinfeld J; Albers P
    BJU Int; 2009 Nov; 104(9 Pt B):1404-12. PubMed ID: 19840021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
    Paffenholz P; Pfister D; Heidenreich A
    Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.